Results 181 to 190 of about 399,115 (333)

CD169+ Macrophage‐Targeted Immunomodulator to Restore Phagocytic Function and Enhance Antigen Presentation for Lymphatic Metastasis Eradication

open access: yesAdvanced Science, EarlyView.
A CD169+ macrophage‐targeted immunomodulator (G‐LNP@S‐D) is developed to co‐deliver a SHP2 inhibitor and STING agonist, thereby restoring phagocytic function, enhancing antigen presentation by CD169+ macrophages, and promoting T cell priming to eradicate lymphatic metastasis.
Xiayun Chen   +9 more
wiley   +1 more source

Irradiated Tumor Cell‐Derived Microparticles Activate Systemic Anti‐Tumor Immunity via the STING/NLRP3/GSDMD Axis in Neutrophils

open access: yesAdvanced Science, EarlyView.
Radiotherapy induces tumor cells to release microparticles (RT‐MPs) into the circulation. The mitochondrial DNA carried by these RT‐MPs activates the STING/NLRP3/GSDMD axis in splenic neutrophils, triggering IL‐1β secretion. This, in turn, enhances dendritic cell function and facilitates the formation of cytotoxic T lymphocytes, thereby promoting ...
Yan Hu   +18 more
wiley   +1 more source

Deciphering the Transcriptomic Signatures of Aging Across Organs in Mice. [PDF]

open access: yesAging Cell
Morsy S   +9 more
europepmc   +1 more source

scPER: A Rigorous Computational Approach to Determine Cellular Subtypes in Tumors Aligned With Cancer Phenotypes From Total RNA Sequencing

open access: yesAdvanced Science, EarlyView.
scPER presents an adversarial‐autoencoder framework that deconvolves bulk total RNA‐seq to quantify tumor‐microenvironment cell types and uncover phenotype‐linked subclusters. Across diverse benchmarks, scPER improves accuracy over existing tools.
Bingrui Li, Xiaobo Zhou, Raghu Kalluri
wiley   +1 more source

Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study. [PDF]

open access: yesLiver Int
Kim JS   +15 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy